Tesamorelin + Ipamorelin
Single vial containing 12mg Tesamorelin + 6mg Ipamorelin — combined GHRH analog and GHRP for synergistic growth hormone pathway research
Select size
For research purposes only. Not for human consumption.
Mechanism of Action
A single-vial combination of 12mg Tesamorelin (a stabilized GHRH analog) and 6mg Ipamorelin (a selective ghrelin/GHS-R1a receptor agonist) designed to stimulate growth hormone release through two complementary pathways simultaneously.
How It Works
- 1
Tesamorelin binds GHRH receptors on the anterior pituitary, driving pulsatile endogenous GH release
- 2
Ipamorelin activates the ghrelin (GHS-R1a) receptor, amplifying GH pulse amplitude without affecting cortisol or prolactin
- 3
Combined GHRH + GHRP action produces synergistic GH/IGF-1 elevation greater than either peptide alone
- 4
Preserves natural pulsatile GH secretion patterns rather than flooding the system continuously
- 5
Tesamorelin's lipolytic profile pairs with Ipamorelin's clean GH-release profile for body-composition research
Key Research Benefits
- Synergistic GH pathway activation
- Visceral adipose tissue (VAT) research
- IGF-1 axis investigation
- Body composition and recovery studies
- Clean GH release (no cortisol/prolactin spike)
- Convenience of dual-peptide single vial
This combination vial contains 12mg lyophilized Tesamorelin + 6mg lyophilized Ipamorelin in a single vial. Reconstitute with bacteriostatic water and store refrigerated (2–8°C) post-reconstitution. For research use only — not for human consumption.